Adalimumab for Inflammatory Osteoarthritis

Sponsor
University of Alberta
Study ID
NCT00686439
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — DRUG
    subcutaneous injection 40mg on alternate weeks
  • adalimumab — DRUG
    subcutaneous injection 40mg every other week

Study Details

We will conduct a pilot study of the effectiveness of adalimumab for inflammatory osteoarthritis.

Key Dates

Start date
Jun 30, 2008
Status verified
Jun 2012
Primary completion
Nov 30, 2010
Completion
Nov 30, 2010

Study Design

Enrollment
20 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: adalimumab

Primary Outcome Measure

OARSI/OMERACT response [ Time Frame: 12 weeks ]

Related Studies